MIFH
ALNY icon

Migdal Insurance & Financial Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,170
Closed -$730K – 585
2021
Q1 		$730K Buy
5,170
+3,208
+164% +$483K 0.01% 275
2020
Q4 		$255K Buy
+1,962
New +$262K ﹤0.01% 287

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Migdal Insurance & Financial Holdings's ALNY Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2021, closing a stake of 5,170 shares — an estimated $730K sold.

Migdal Insurance & Financial Holdings first reported a position in ALNY in Q4 2020 and held it in 2 quarters. The position peaked at $730K in Q1 2021. 401 funds tracked by Wall St. Rank hold ALNY as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Alnylam Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 5,170 Alnylam Pharmaceuticals shares in Q2 2021, an estimated $730K.
  • Migdal Insurance & Financial Holdings first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Alnylam Pharmaceuticals position peaked at $730K in Q1 2021.
  • 401 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.